Korro Bio (NASDAQ:KRRO) Major Shareholder Acquires 207,100 Shares

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Edward Mathers bought 207,100 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The stock was purchased at an average cost of $11.11 per share, with a total value of $2,300,881.00. Following the completion of the purchase, the insider directly owned 1,297,893 shares of the company’s stock, valued at $14,419,591.23. This represents a 18.99% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Korro Bio Trading Down 2.2%

Shares of KRRO traded down $0.26 during mid-day trading on Thursday, reaching $11.50. The company’s stock had a trading volume of 92,041 shares, compared to its average volume of 184,676. The business has a 50-day simple moving average of $10.90 and a two-hundred day simple moving average of $20.23. Korro Bio, Inc. has a 1-year low of $5.20 and a 1-year high of $55.89. The stock has a market cap of $108.33 million, a P/E ratio of -1.22 and a beta of 2.98.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($5.32) EPS for the quarter. Korro Bio had a negative net margin of 1,199.53% and a negative return on equity of 68.87%. The company had revenue of $1.29 million during the quarter. Research analysts anticipate that Korro Bio, Inc. will post -9.52 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on KRRO shares. Weiss Ratings restated a “sell (d-)” rating on shares of Korro Bio in a report on Friday, January 9th. William Blair raised shares of Korro Bio from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. Clear Str upgraded Korro Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 18th. Royal Bank Of Canada lowered Korro Bio from an “outperform” rating to a “sector perform” rating in a report on Thursday, November 13th. Finally, Chardan Capital upgraded shares of Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 price target on the stock in a research report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $50.38.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Nantahala Capital Management LLC bought a new position in Korro Bio in the 4th quarter valued at approximately $4,806,000. TCG Crossover Management LLC purchased a new position in shares of Korro Bio in the third quarter worth approximately $19,937,000. JPMorgan Chase & Co. boosted its stake in shares of Korro Bio by 6,185.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 199,249 shares of the company’s stock worth $9,542,000 after acquiring an additional 196,079 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in Korro Bio during the third quarter valued at about $4,319,000. Finally, Raymond James Financial Inc. increased its holdings in Korro Bio by 78.6% in the 3rd quarter. Raymond James Financial Inc. now owns 148,971 shares of the company’s stock worth $7,134,000 after acquiring an additional 65,579 shares in the last quarter. 13.18% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Korro Bio

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Multiple major shareholders and investors materially bought stock on March 10 — including Anthony A. Florence Jr., Paul E. Walker, Mohamad Makhzoumi, Edward T. Mathers, Forest Baskett, Rick Yang, Scott D. Sandell and Enterprise Associates 17 New — each acquiring 207,100 shares at $11.11, increasing their individual stakes by ~18.99%. Insider and large‑holder purchases often signal confidence in company prospects. SEC Filing (example)
• Positive Sentiment: Company reported an oversubscribed $85 million private placement that management says extends the cash runway into H2 2028 — reduces near‑term financing risk and supports ongoing programs. The corporate update also cited nominations of development candidates (KRRO‑121 for hyperammonemia indications and an advanced GalNAc conjugate program for alpha‑1 antitrypsin deficiency), indicating R&D progress. GlobeNewswire Press Release
• Negative Sentiment: Quarterly results were weak: KRRO reported a Q4 EPS loss of $(5.32), far worse than the consensus loss of $(1.93), with only $1.29M in revenue and a deeply negative net margin and ROE. The magnitude of the miss raises execution and cost concerns and likely pressured the stock despite the financing and insider buying. Zacks Coverage of Q4 Results

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.